Skip to main content

HomeResearchCompareCartalax vs Leuphasyl

Peptide Comparison

Cartalax vs Leuphasyl

Both are Skin & Joint peptides.

Cartalax

Ala-Glu-Asp-Arg

Skin & JointLow Risk

Half-life: Unknown

4 providers listed

Full Cartalax profile →
vs

Leuphasyl

Acetyl Tetrapeptide-2

Skin & JointLow Risk

Half-life: N/A (topical)

No providers listed yet

Full Leuphasyl profile →

Quick Verdict

Cartalax

Risk

Low

Leuphasyl

Risk

Low

Side-by-Side Comparison

Cartalax
Leuphasyl
Category
Skin & Joint
Skin & Joint
Risk Level
Low Risk
Low Risk
Half-life
Unknown
N/A (topical)
FDA Status
not evaluated
not evaluated
Admin Routes
subcutaneous injection, oral
topical
Availability
Research Only
Research Only
Providers
4 listed
None listed

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

A Khavinson peptide bioregulator targeting cartilage tissue. Promotes chondrocyte activity and cartilage matrix regeneration; studied for osteoarthritis and joint degeneration.

Research Areas

cartilage regenerationjoint repairchondrocyte function support

About Leuphasyl

Tetrapeptide that mimics enkephalin to modulate facial muscle contraction; competes with enkephalin for opioid receptor sites in neuromuscular junctions; reduces repetitive muscle micro-contractions

A neuromodulating peptide that reduces expression lines via the enkephalin pathway, distinct from SNARE-inhibiting peptides (Argireline, SNAP-8). Complements those actives through a different mechanism.

Research Areas

expression line reductionfacial muscle relaxationenkephalin pathway modulation

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More skin joint Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.